Drug Trial Radar · NCT01186861
Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
205
Actual
Start
Mar 4, 2011
Primary completion
Jul 1, 2013
Study completion Mar 11, 2015
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Aug 23, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, randomized, double-blind, placebo-controlled, phase 2 study with a 1:1 randomization scheme.
Conditions
- Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Interventions
OSI-906Drug
Tablet administered with food and with up to 200 mL of water
erlotinibDrug
Tablet administered at least 2 hours after food with up to 200 mL of water
placeboDrug
Tablet administered at least 2 hours after food with up to 200 mL of water
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Progression Free Survival (PFS) of maintenance OSI-906 plus erlotinib, or placebo plus erlotinib in patients with nonprogression following four cycles of first-line platinum-based chemotherapy for advanced NSCLC in the overall populationTime frame: 22 months
Locations
69 sites in 9 countries. Site status is shown where the registry gives one.
Site US10007
Jacksonville, Florida
Site US10001
Port Saint Lucie, Florida
Site US10002
Albany, Georgia
Site US10008
Chicago, Illinois
Site US10011
Scarborough, Maine
Site US10004
Greensboro, North Carolina
Site US10010
Winston-Salem, North Carolina
Site BR55005
Barretos, Brazil
Site BR55004
Brasília, Brazil
Site BR55015
Cachoeiro de Itapemirim, Brazil
Site BR55011
Florianópolis, Brazil
Site BR55003
Fortaleza, Brazil
Site BR55016
Goiânia, Brazil
Site BR55006
Ijuí, Brazil
Site BR55001
Itajaí, Brazil
Site BR55008
Piracicaba, Brazil
Site BR55013
Porto Alegre, Brazil
Site BR55014
Porto Alegre, Brazil
Site BR55012
Ribeirão Preto, Brazil
Site BR55002
Rio de Janeiro, Brazil
Site BR55007
São Paulo, Brazil
Site CA11001
Oshawa, Canada
Site CA11004
Ottawa, Canada
Site CA11006
Toronto, Canada
Site CA11002
Toronto, Canada
Site DE49014
Berlin, Germany
Site DE49008
Cologne, Germany
Site DE49011
Dortmund, Germany
Site DE49003
Großhansdorf, Germany
Site DE49001
Heidelberg, Germany
Site DE49002
Hemer, Germany
Site DE49009
Homburg/Saar, Germany
Site DE49006
Immenhausen, Germany
Site DE49012
Karlsruhe, Germany
Site DE49015
Kassel, Germany
Site DE49010
Lübeck, Germany
Site DE49013
Mainz, Germany
Site DE49005
Minden, Germany
Site PL48002
Elblag, Poland
Site PL48005
Szczecin, Poland
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.